65,437 trials
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 as Compared to Placebo — 0.18; -0.68; -0.91; -0.92 percentage of HbA1c — p=<0.0001
Mandibular Anterior Crowding · Piezocision · Pain Perception
Primary: Number of Days to Complete Alignment of Mandibular Anterior Teeth Based on Little's Irregularity Index — 112; 102.13 Days to complete alignment — p=<0.05
Sleep Apnea, Obstructive
Primary: Experimental Cold-induced Pain - IGFBP-1 — 0.0025 [sec/(mcg/mL)] /pg/mL — p=<0.05
Vaginismus
Primary: Ability to Achieve Pain Free Intercourse. — 90.3 percentage of participants
Septic Shock
Primary: 28-day Mortality — 19; 23 Participants
Morbid Obesity
Primary: Mean Percentage Total Body Weight Loss — 15.8; 20.7; 20.3 % of total body weight loss
Obesity · Weight Loss
Primary: The Primary Outcome Will be the Leptin Levels at Baseline and 8 Weeks — 39.5; 13.4 ng/ml
Malaria
Primary: Anti-Circumsporozoite (Anti-CS) Antibody Titers — 319.6; 241.4; 302.3; 285.8 Titers
Osteoarthritis · Rheumatoid Arthritis · Avascular Necrosis
Primary: American Shoulder and Elbow Society Score (ASES) Pain Assessment — 5.4 Scores on a scale
HIV
Primary: Number of Women Who Came With Their Partners and Received Couple Counseling and Testing — 52; 70 Female participants receiving CHTC
Anxiety · Depression · PTSD
Primary: MOVE! Attendance — 5.9; 5.8 number of sessions
Primary Insomnia
Primary: Overall Average Sleep Continuity Profile — 28.8; 33.8; 19.1; 20.7 minutes
Cancer
Primary: Pain — 0; 0; 0; 0 units on a scale
Idiopathic Parkinson's Disease
Primary: Maximum Percent Change From Baseline in Movement Disorder Society-Sponsor Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Day 7…
Cardiovascular Diseases
Primary: Major Cardiovascular Disease Event — 3182; 527 Cardiovascular disease event